...
首页> 外文期刊>International Journal of Cardiology >Assessment of myocardial perfusion and viability by Positron Emission Tomography
【24h】

Assessment of myocardial perfusion and viability by Positron Emission Tomography

机译:正电子发射断层扫描评估心肌灌注和生存能力

获取原文
获取原文并翻译 | 示例
           

摘要

An important evolution has taken place recently in the field of cardiovascular Positron Emission Tomography (PET) imaging. Being originally a highly versatile research tool that has contributed significantly to advance our understanding of cardiovascular physiology and pathophysiology, PET has gradually been incorporated into the clinical cardiac imaging portfolio contributing to diagnosis and management of patients investigated for coronary artery disease (CAD). PET myocardial perfusion imaging (MPI) has an average sensitivity and specificity around 90% for the detection of angiographically significant CAD and it is also a very accurate technique for prognostication of patients with suspected or known CAD. In clinical practice, Rubidium-82 ( 82Rb) is the most widely used radiopharmaceutical for MPI that affords also accurate and reproducible quantification in absolute terms (ml/min/g) comparable to that obtained by cyclotron produced tracers such as Nitrogen-13 ammonia (13N-ammonia) and Oxygen-15 labeled water ( 15O-water). Quantification increases sensitivity for detection of multivessel CAD and it may also be helpful for detection of early stages of atherosclerosis or microvascular dysfunction. PET imaging combining perfusion with myocardial metabolism using 18F-Fluorodeoxyglucose ( 18F FDG), a glucose analog, is an accurate standard for assessment of myocardial hibernation and risk stratification of patients with left ventricular dysfunction of ischemic etiology. It is helpful for guiding management decisions regarding revascularization or medical treatment and predicting improvement of symptoms, exercise capacity and quality of life post-revascularization. The strengths of PET can be increased further with the introduction of hybrid scanners, which combine PET with computed tomography (PET/CT) or with magnetic resonance imaging (PET/MRI) offering integrated morphological, biological and physiological information and hence, comprehensive evaluation of the consequences of atherosclerosis in the coronary arteries and the myocardium.
机译:最近在心血管正电子发射断层扫描(PET)成像领域发生了重要的发展。 PET最初是一种用途广泛的研究工具,对增进我们对心血管生理学和病理生理学的理解做出了巨大贡献,逐渐将其纳入临床心脏成像产品组合,从而有助于诊断和管理接受冠状动脉疾病(CAD)的患者。 PET心肌灌注显像(MPI)对血管造影显着性CAD的检测具有90%左右的平均敏感性和特异性,对于可疑或已知CAD的患者进行预后也是一种非常准确的技术。在临床实践中,Rub 82(82Rb)是MPI的最广泛使用的放射性药物,与以回旋加速器生产的示踪剂如13号氮(Nt)所获得的定量相比,其绝对值(ml / min / g)也可提供准确且可重现的定量。 13 N-氨)和Oxygen-15标记的水(15O-水)。量化提高了检测多支血管CAD的敏感性,也可能有助于早期发现动脉粥样硬化或微血管功能障碍。 PET成像结合使用葡萄糖类似物18F-氟脱氧葡萄糖(18F FDG)将灌注与心肌代谢相结合,是评估缺血性病因左心功能不全患者的心肌冬眠和危险分层的准确标准。它有助于指导有关血运重建或药物治疗的管理决策,并预测血运重建后症状,运动能力和生活质量的改善。通过引入混合扫描仪,可以进一步提高PET的强度,该扫描仪将PET与计算机断层扫描(PET / CT)或磁共振成像(PET / MRI)相结合,可提供整合的形态,生物学和生理学信息,因此可以对冠状动脉和心肌中动脉粥样硬化的后果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号